CS
AMLX icon

Credit Suisse’s Amylyx Pharmaceuticals AMLX Stock Holding History

Credit Suisse’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$104K Sell
36,643
-1,409
-4% -$18.4K ﹤0.01% 2931
2023
Q4 		$560K Buy
38,052
+3,739
+11% +$57.3K ﹤0.01% 2677
2023
Q3 		$628K Buy
34,313
+996
+3% +$21.1K ﹤0.01% 2564
2023
Q2 		$719K Buy
+33,317
New +$900K ﹤0.01% 2600
2023
Q1 		– Sell
-2
Closed -$74 – 3275
2022
Q4 		$74 Sell
2
-195
-99% -$6.92K ﹤0.01% 3615
2022
Q3 		$6K Buy
197
+186
+1,691% +$4.64K ﹤0.01% 3632
2022
Q2 		$0 Buy
+11
New +$131 ﹤0.01% 3899

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse's AMLX Position: Q1 2024 in Review

Credit Suisse reduced its Amylyx Pharmaceuticals (AMLX) stake by 3.7% in Q1 2024, selling an estimated $18.4K and leaving 36,643 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #2931.

Credit Suisse first reported a position in AMLX in Q2 2022 and has held it in 7 quarters since. The position peaked at $719K in Q2 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • Credit Suisse held 36,643 shares of Amylyx Pharmaceuticals worth $104K as of Q1 2024.
  • Credit Suisse sold 1,409 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $18.4K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2931 holding.
  • Credit Suisse first reported a position in Amylyx Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
  • Credit Suisse's Amylyx Pharmaceuticals position peaked at $719K in Q2 2023.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.